Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRTE7A2-01 TCR-T in HPV16+ Solid Tumors
NCT06358053Phase 1Not yet recruiting
- Sponsor
- CorreGene
- Start
- Apr 2024
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
01
Overview
Phase 1, open-label, single-arm trial of CRTE7A2-01 in Cervical Cancer (CC), anal cancer, head and neck cancer (HNC) and 1 more, sponsored by CorreGene. Primary endpoints: Dose-Limiting Toxicity at 28 days, Recommended Phase 2 Dose at 2 years and 1 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
CRTE7A2-01
03
Conditions
Cervical Cancer (CC)anal cancerhead and neck cancer (HNC)solid tumor
Beyond the preview
Go deeper on NCT06358053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06358053.